Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

American College of Cardiology Meeting In Brief: Antidepressant therapy post-MI

Executive Summary

Antidepressant therapy post-MI: In 81 myocardial infarction survivors, the SSRI paroxetine (SmithKline Beecham's Paxil) and the tricyclic nortryptiline (Sandoz' Pamelor and generics) were equally effective in treating clinical depression, although nortryptiline was associated with more adverse events, Mitchell Finkel, MD, University of Pittsburgh, reported March 26. Two of 41 paroxetine patients discontinued therapy due to AEs, one of which was cardiac related, compared to eight of 40 nortryptiline patients, seven of which were cardiac related. Nortryptiline was associated with increases in heart rate and QTc intervals, while paroxetine was not associated with any significant changes in heart rate, blood pressure or pro-arrhythmic events...
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027933

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel